Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases
申请人:Janssen Sciences Ireland Unlimited Company
公开号:US11053235B2
公开(公告)日:2021-07-06
The application describes dihydropyrimidine derivatives which are useful in the treatment or prevention of HBV infection or of HBV-induced diseases, more particularly of HBV chronic infection or of diseases induced by HBV chronic infection, as well as pharmaceutical or medical applications thereof.
该申请描述了可用于治疗或预防 HBV 感染或 HBV 引起的疾病,特别是 HBV 慢性感染或 HBV 慢性感染引起的疾病的二氢嘧啶衍生物,以及其在制药或医疗方面的应用。